1560 Journal of Medicinal Chemistry, 2006, Vol. 49, No. 5
Carraro et al.
breast cancer. Epidemiol. Biomarkers PreV. 1999, 8, 855-861).
Among this tumor type, ductal infiltrating carcinoma (DIC) of the
breast is the most common and potentially aggressive form of cancer
(Donegan, W. L. Tumor-related prognostic factors for breast cancer.
CA Cancer J. Clin. 1997, 47, 28-51), for the treatment of which
there is no approved drug, yet.
one Monte dei Paschi di Siena is gratefully acknowledged. We
thank Dr. Giovanni Gaviraghi (Sienabiotech S.p.A.) for helpful
discussion. The "Centro Universitario per l′Informatica e la
Telematica" of the University of Siena is also acknowledged.
(23) Carraro, F.; Pucci, A.; Naldini, A.; Schenone, S.; Bruno, O.; Ranise,
A.; Bondavalli, F.; Brullo, C.; Fossa, P.; Menozzi, M.; Mosti, L.;
Manetti, F.; Botta, M. Pyrazolo[3,4-d]pyrimidines Endowed with
Antiproliferative Activity on Ductal Infiltrating Carcinoma Cells. J.
Med. Chem. 2004, 47, 1595-1598.
Supporting Information Available: Experimental details of
the synthesis, spectral data, and elemental analysis data of some
representative compounds. This material is available free of charge
(24) Bondavalli, F.; Botta, M.; Bruno, O.; Ciacci, A.; Corelli, F.; Fossa,
P.; Lucacchini, A.; Manetti, F.; Martini, C.; Menozzi, G.; Mosti, L.;
Ranise, A.; Schenone, S.; Tafi, A.; Trincavelli, M. L. Synthesis,
molecular modeling studies, and pharmacological activity of selective
A1 receptor antagonists. J. Med. Chem. 2002, 45, 4875-4887.
(25) Ve´liz, E. A.; Beal, P. A. C6 substitution of inosine using hexam-
ethylphosphorous triamide in conjunction with carbon tetrahalide or
N-halosuccinimide. Tetrahedron Lett. 1999, 41, 1695-1697.
(26) Liu, Y.; Bishop, A.; Witucki, L.; Kraybill, B.; Shimizu, E.; Tsien,
J.; Ubersax, J.; Blethrow, J.; Morgan, D. O.; Shokat, K. M. Structural
basis for selective inhibition of Src family kinases by PP1. Chem.
Biol. 1999, 6, 671-678.
References
(1) Neet, K.; Hunter, T. Vertebrate nonreceptor protein-tyrosine kinase
families. Genes Cells 1996, 1, 147-169.
(2) Hunter, T. The role of tyrosine phosphorylation in cell growth and
disease. HarVey Lect. 1998, 94, 81-119.
(3) Ullrich, A.; Schlessinger, J. Signal transduction by receptors with
tyrosine kinase activity. Cell 1990, 61, 203-212.
(4) van der Geer, P.; Hunter, T.; Lindberg, R. A. Receptor protein-
tyrosine kinases and their signal transduction pathways. Annu. ReV.
Cell Biol. 1994, 10, 251-337.
(5) Brown, M. T.; Cooper, J. A. Regulation, substrates and functions of
src. Biochim. Biophys. Acta 1996, 1287, 121-149.
(6) Thomas, S. M.; Brugge, J. S. Cellular functions regulated by Src
family kinases. Annu. ReV. Cell DeV. Biol. 1997, 13, 513-609.
(7) Abram, C. L.; Courtneidge, S. A. Src family tyrosine kinases and
growth factor signaling. Exp. Cell Res. 2000, 254, 1-13.
(8) Martin, G. S. The hunting of the Src. Nat. ReV. Mol. Cell Biol. 2001,
2, 467-475.
(9) Frame, M. C.; Fincham, V. J.; Carragher, N. O.; Wyke, J. A. v-Src’s
hold over actin and cell adhesions. Nat. ReV. Mol. Cell Biol. 2002,
3, 233-245.
(10) Bjorge, J. D.; Jakymiw, A.; Fujita, D. J. Selected glimpses into the
activation and function of Src kinase. Oncogene 2000, 19, 5620-
5635.
(11) Mazurenko, N. N.; Kogan, E. A.; Zborovskaya, I. B.; Kisseljov, F.
L. Expression of pp60c-src in human small cell and non small cell
lung carcinomas. Eur. J. Cancer 1992, 28, 372-377.
(12) Irby, R. B.; Yeatman, T. J. Role of Src expression and activation in
human cancer. Oncogene 2000, 19, 5636-5642.
(13) Budde, R. J.; Ke, S.; Levin, V. A. Activity of pp60c-src in 60 different
cell lines derived from human tumors. Cancer Biochem. Biophys.
1994, 14, 171-175.
(14) Irby, R. B.; Mao, W.; Coppola, D.; Kang, J.; Loubeau, J. M.; Trudeau,
W.; Karl, R.; Fujita, D. J.; Jove, R.; Yeatman, T. J. Activating SRC
mutation in a subset of advanced human colon cancers. Nat. Genet.
1999, 21, 187-190.
(15) Verbeek, B. S.; Vroom, T. M.; Adriaansen-Slot, S. S.; Ottenhoff-
Kalff, A. E.; Geertzema, J. G.; Hennipman, A.; Rijksen, G. c-Src
protein expression is increased in human breast cancer. An immu-
nohistochemical and biochemical analysis. J. Pathol. 1996, 180, 383-
388.
(16) Barrios Sosa, A. C.; Boschelli, D. H.; Wu, B.; Wang, Y.; Golas, J.
M. Further studies on ethenyl and ethynyl-4-phenylamino-3-quino-
linecarbonitriles: identification of a subnanomolar Src kinase inhibi-
tor. Bioorg. Med. Chem. Lett. 2005, 15, 1743-1747.
(17) Ple´, P. A.; Green, T. P.; Hennequin, L. F.; Curwen, J.; Fennel, M.;
Allen, J.; Lambert-van der Brempt, C.; Costello, G. Discovery of a
new class of anilinoquinazoline inhibitors with high affinity and
specificity for the tyrosine kinase domain of c-Src. J. Med. Chem.
2004, 47, 871-887.
(18) Altmann, E.; Widler, L.; Missbach, M. N(7)-substituted-5-aryl-
pyrrolo[2,3-d]pyrimidines represent a versatile class of potent inhibi-
tors of the tyrosine kinase c-Src. Mini ReV. Med. Chem. 2002, 2,
201-208.
(19) Hanke, J. H.; Gardner, J. P.; Dow, R. L.; Changelian, P. S.; Brissette,
W. H.; Weringer, E. J.; Pollok, B. A.; Connelly, P. A. Discovery of
a novel, potent, and Src family-selective tyrosine kinase inhibitor.
Study of Lck- and FynT-dependent T cell activation. J. Biol. Chem.
1996, 271, 695-701.
(20) Schenone, S.; Bruno, O.; Ranise, A.; Bondavalli, F.; Brullo, C.; Fossa,
P.; Mosti, L.; Menozzi, G.; Carraro, F.; Naldini, A.; Bernini, C.;
Manetti, F.; Botta M. New Pyrazolo[3,4-d]pyrimidines Endowed with
A431 Antiproliferative Activity and Inhibitory Properties of Src
Phosphorylation. Bioorg. Med. Chem. Lett. 2004, 14, 2511-2517.
(21) Sheffield, L. G. C-Src activation by ErbB2 leads to attachment-
independent growth of human breast epithelial cells. Biochem.
Biophys. Res. Commun. 1998, 250, 27-31.
(22) It is well-known that breast cancer has been the most common
malignancy among western women and the incidence rates of first
primary breast cancer have been increasing over time (Chen, Y.;
Thompson, W.; Semenciw, R.; Mao, Y. Epidemiology of controlateral
(27) Thomas, S. M.; Brugge, J. S. Cellular functions regulated by Src
family kinases. Annu. ReV. Cell DeV. Biol. 1997, 13, 513-609.
(28) Maga, G. Manuscript in preparation.
(29) Dehm, S. M.; Bonham, K. SRC gene expression in human cancer:
the role of transcriptional activation. Biochem. Cell. Biol. 2004, 82,
263-74.
(30) Botta, M. Manuscript in preparation.
(31) Stout, T. J.; Foster, P. G.; Matthews, D. J. High-Throughput Structural
Biology in Drug Discovery: Protein Kinases. Curr. Pharm. Des.
2004, 10, 1069-1082.
(32) Noble, M. E.; Endicott, J. A.; Brown, N. R.; Johnson, L. N. The
cyclin box fold: protein recognition in cell-cycle and transcription
control. Trends Biochem. Sci. 1997, 22, 482-487.
(33) De Murcia, G.; Menissier, D. M. Poly(ADP-ribose) polymerase: a
molecular nick-sensor. Trends Biochem. Sci. 1994, 19, 172-176.
(34) Tewari, M.; Quan, L. T.; O’Rourke, K.; Desnoyers, S.; Zeng, Z.;
Beidler, D. R.; Poirier, G. G.; Salvesen, G. S.; Dixit, V. M. Yama/
CPP32 beta, a mammalian homolog of CED-3, is a CrmA-inhibitable
protease that cleaves the death substrate poly(ADP-ribose) poly-
merase. Cell 1995, 81, 801-809.
(35) Cory, S. Regulation of lymphocyte survival by the bcl-2 gene family.
Annu. ReV. Immunol. 1995, 13, 513-543.
(36) Cowan-Jacob, S. W.; Fendrich, G.; Manley, P. W.; Jahnke, W.;
Fabbro, D.; Liebetanz, J.; Meyer, T. The Crystal Structure of a C-Src
Complex in an Active Conformation Suggests Possible Steps in
C-Src Activation. Structure 2005, 13, 861-871.
(37) Morris, G. M.; Goodsell, D. S.; Halliday, R. S.; Huey, R.; Hart, W.
E.; Belew, R. K.; Olson, A. J. Automated Docking Using a
Lamarckian Genetic Algorithm and Empirical Binding Free Energy
Function. J. Comput. Chem. 1998, 19, 1639-1662.
(38) Traxler, P.; Bold, G.; Frei, J.; Lang, M.; Lydon, N.; Mett, H.;
Buchdunger, E.; Meyer, T.; Mueller, M.; Furet, P. Use of a
pharmacophore model for the design of EGF-R tyrosine kinase
inhibitors: 4-(phenylamino)pyrazolo[3,4-d]pyrimidines. J. Med. Chem.
1997, 40, 3601-16.
(39) Zhu, X.; Kim, J. L.; Newcomb, J. R.; Rose, P. E.; Stover, D. R.;
Toledo, L. M.; Zhao, H.; Morgenstern, K. A. Structural analysis of
the lymphocyte-specific kinase Lck in complex with non-selective
and Src family selective kinase inhibitors. Structure Fold. Des. 1999,
7, 651-61.
(40) MacroModel version 8.5. 2003. Schrodinger, L.L.C.
(41) Cona, A.; Manetti, F.; Leone, R.; Corelli, F.; Tavladoraki, P.;
Polticelli, F.; Botta, M.Molecular Basis for the Binding of Competi-
tive Inhibitors of Maize Polyamine Oxidase. Biochemistry 2004, 43,
3426-3435.
(42) Fidler, I. J. The organ microenvironment and cancer metastasis.
Differentiation 2002, 70, 498-505.
(43) Fidler, I. J. The pathogenesis of cancer metastasis: the 'seed and
soil′ hypothesis revisited. Nat. ReV. Cancer 2003, 3, 453-458.
(44) Giard, D. J.; Aaronson, S. A.; Todaro, G. J.; Arnstein, P.; Kersey, J.
H.; Dosik, H.; Parks, W. P. In vitro cultivation of human tumors:
establishment of cell lines derived from a series of solid tumors. J.
Natl. Cancer Inst. 1973, 51, 1417-1423.
(45) Minafra, S.; Morello, V.; Glorioso, F.; La Fiura, A. M.; Tomasino,
R. M.; Feo, S.; McIntosh, D.; Woolley, D. E. A new cell line (8701-
BC) from primary ductal infiltrating carcinoma of human breast. Br.
J. Cancer 1989, 60, 185-192.
(46) Mosmann, T. Rapid colorimetric assay for cellular growth and
survival: application to proliferation and cytotoxicity assays. J.
Immunol. Methods 1983, 65, 55-63.